VSTM (VSTM) Earnings Call Analysis

14/25

Growth 5 Margin 3 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

14
Veristem Oncology (VSTM) Q2 2026: $90M Non-Dilutive Funding Secures Pipeline Execution Through 2027
August 07, 2026
13
VeriSTEM Oncology (VSTM) Q1 2026: COPAQ Prescriber Base Expands to 400, Launching Next-Phase Growth
May 08, 2026
11
Veristem Oncology (VSTM) Q4 2025: COPAQ Launch Drives $17.5M Revenue, Pipeline Progress Sets Up 2026 Catalysts
March 05, 2026
12
Verisim Oncology (VSTM) Q3 2025: 133 Prescribers Drive First Full Quarter Launch Momentum
November 04, 2025
6
Verastem (VSTM) Q2 2025: $2.1M Launch Revenue Marks Breakthrough in KRAS-Mutated LGSOC Treatment
August 07, 2025

Browse all companies